Navigation Links
Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Date:5/25/2011

Marsden NHS Foundation Trust, and lead author.  "The data indicate that abiraterone acetate has the potential to meet a significant unmet need for these patients."

Androgens are hormones that promote the development and maintenance of male sex characteristics.   However, in prostate cancer, androgens can help fuel the tumor's growth.  Androgen production primarily occurs in the testes and adrenal glands; in men with prostate cancer, the tumor tissue is an additional source of androgens. ZYTIGA is an oral androgen biosynthesis inhibitor that works by selectively inhibiting the CYP17 enzyme complex, which is required for the production of androgens at these three sources.

The U.S. Food and Drug Administration (FDA) approved ZYTIGA on April 28, 2011 for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

The results of this randomized, double-blind, placebo-controlled study were presented in part during a late-breaking presentation at the Presidential Symposium at the 35th Annual European Society for Medical Oncology Congress in Milan, Italy on October 11, 2010, and have been presented at several conferences since then.

Study Design

ZYTIGA, in combination with prednisone, was evaluated in a Phase 3, randomized, placebo-controlled, multicenter clinical study in patients who had received prior chemotherapy containing a taxane (N = 1,195).  A total of 1,195 patients were randomized 2:1 to receive ZYTIGA 1000 milligrams (mg) daily in combination with prednisone 5 mg twice daily or placebo in combination with prednisone 5 mg twice daily (control arm).  The primary endpoint was overall survival.

Indication

ZYTIGA (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) w
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless ... Robert F. Doman , Executive Chairman and Interim ... Noble Financial Capital Markets, Tenth Annual Equity Conference. ... corporate presentation to prospective corporate partners and investors ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... , Jan. 14, 2014 ... ), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced that it ... will be approximately $53 million, bringing expected full-year ... "Our full-year revenue growth of 87% for 2013 ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... With chronic respiratory disorders, method cuts death risk, study ... with chronic respiratory disorders who receive early non-invasive ventilation ... likely to suffer respiratory failure or die, a Spanish ... on mechanical ventilation. All of them had high levels ...
... , , , , ... KAD ), a leading provider of home care, medical staffing, and pharmacy services ... ended June 30, 2009. , , For the ... with $26.8 million for the same period last year. Arcadia reported a ...
... The Gilchrist Institute for the Achievement Sciences, an economic ... health care reform aimed at members of Congress and the ... Gilchrist Institute Director Dr. Robert Flower states, "We are challenging ... the application that needs reform and the administration that needs ...
... 13 Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical ... June 30, 2009. , , Revenues for the ... $2.7 million for the corresponding period in 2008. The increase ... IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical trial recorded in the most ...
... ... introduced the supplement NourishLife speak™ which combines omega-3 and vitamin E ... A recent study published in the July issue of Alternative ... apraxia taking a combination of omega-3 and vitamin E noted significant ...
... ... proud to announce the September 1 opening of its newest office in ... population from Hoboken, Jersey City and the Newport area and our physicians ... services. The Hoboken office is partly the result of a merger with ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:Arcadia Resources Announces First Quarter Results 2Health News:Arcadia Resources Announces First Quarter Results 3Health News:Arcadia Resources Announces First Quarter Results 4Health News:Arcadia Resources Announces First Quarter Results 5Health News:Arcadia Resources Announces First Quarter Results 6Health News:Arcadia Resources Announces First Quarter Results 7Health News:Arcadia Resources Announces First Quarter Results 8Health News:Arcadia Resources Announces First Quarter Results 9Health News:Arcadia Resources Announces First Quarter Results 10Health News:Arcadia Resources Announces First Quarter Results 11Health News:Arcadia Resources Announces First Quarter Results 12Health News:Arcadia Resources Announces First Quarter Results 13Health News:Arcadia Resources Announces First Quarter Results 14Health News:Arcadia Resources Announces First Quarter Results 15Health News:Institute Chastises Congress on Health Care Reforms, Offers Five-Point Program for Reducing Health Care Costs by 50% 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 3Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 4Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 5Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 6Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 8Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 9Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 2Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 3Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 4
... NOW RSV Test is one of the easiest ... results are available in 15 minutes with no ... to parents prior to the child leaving the ... prior to hospital admission to help control the ...
... BinaxNOW Influenza A & B Test ... flu test on the market just ... influenza A and influenza B using ... Now you can focus on the ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
... Clearview hCG Combo with Reference ... detection of human chorionic gonadotropin ... specimens. This test kit is ... result and is intended for ...
Medicine Products: